Clinical trial
Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer
NCT00191243 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191243 |
|---|---|
| Title | Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer |
| Official title | A Randomized Phase II Study Comparing Single-Agent Docetaxel to Alternating Docetaxel-Gemcitabine as Primary Chemotherapy in Patients With Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, docetaxel |
| Enrollment | 237 |
| Start date | Mar 1, 2002 |
| Primary completion | Aug 1, 2007 |
| Completion | Apr 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 12, 2019 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: